1. Pink Sheet
  2. >>Agency Leadership

Lauren Silvis To Depart US FDA, Adding To High-Level String Of Agency Turnover In 2019

 
• By Michael Cipriano

Lauren Silvis will leave her post as chief of staff at the US FDA in the next several weeks, when she will be replaced by associate commissioner for strategic initiatives and external affairs Keagan Lenihan.

FDAEntrance_1200x675
Turnover among senior FDA leaders continues to mount in 2019.

The list of high-level staffers departing the US Food and Drug Administration in 2019 continues to grow, with chief of staff Lauren Silvis becoming the latest set to leave her post at the agency.

Silvis, who previously served as deputy center director for policy at the Center for Devices and Radiological Health, will leave the agency in the next several weeks. Former FDA commissioner Scott Gottlieb appointed her to the chief of staff position in July 2017 after three months of serving in the post in an acting capacity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.